UroMed
This article was originally published in The Gray Sheet
Executive Summary
Voluntary bankruptcy filing under Chapter 7 in Boston federal court, announced May 15, "will result in the complete liquidation of the company's assets," UroMed says. The firm, doing business under the name Alliant Medical Technologies, offers brachytherapy seeds and needles for prostate cancer, treatment planning software for brachytherapy and external beam radiation therapy, and the CaverMap surgical aid for prostate and colorectal cancer surgery. Revenues in 2001 reached $6.1 mil., up 41.6%. However, the firm was unable to commercialize its products successfully, generating an accumulated deficit of $117.2 mil. as of December 2001...
You may also be interested in...
Blue Torch Aims Low: Negative Medicare NCD Could Boost Business, It Says
Blue Torch Medical paradoxically expects that a Medicare national non-coverage decision for its CaverMap diagnostic to assess a patient's risk of impotency after radical prostatectomy will lead to increased sales
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.